Tarsus Pharmaceuticals, Inc.·4

Jun 29, 4:30 PM ET

PYOTT DAVID E I 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 29, 2026

Research Summary

AI-generated summary of this filing

Updated

Tarsus (TARS) Director David Pyott Receives Awards

What Happened
David E. Pyott, a non‑employee director of Tarsus Pharmaceuticals (TARS), was granted a mix of stock option(s) and restricted stock units (RSUs) on 2026-06-25. The awards consist of 3,837 option/award units, 2,417 RSUs, and 806 RSUs (total = 7,060 derivative units). Each grant is reported at $0.00 per unit (these are compensation awards, not open‑market purchases).

Key Details

  • Transaction date: 2026-06-25; Filing date (Form 4): 2026-06-29. The filing was 4 days after the transaction (Form 4s are generally due within 2 business days), so this appears to be late.
  • Reported amounts/prices: 3,837 units @ $0.00; 2,417 units @ $0.00; 806 units @ $0.00. Aggregate = 7,060 derivative units; reported acquisition value $0.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes/vesting:
    • F1: Annual option for non‑employee director; vests in full one year after grant (continuous service).
    • F2: Each RSU equals a contingent right to one common share.
    • F3: RSUs vest in full one year after grant (continuous service).
    • F4: RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027 (continuous service).

Context
These are compensation awards for board service (derivative grants: options and RSUs). Such awards are routine for non‑employee directors and do not reflect an open‑market purchase or sale. The vesting schedules mean the shares (or option value) will only be realized if the director remains in service and any applicable vesting conditions are met.

Insider Transaction Report

Form 4
Period: 2026-06-25
Transactions
  • Award

    Stock Option (right to buy)

    [F1]
    2026-06-25+3,8373,837 total
    Exercise: $64.34Exp: 2036-06-24Common Stock (3,837 underlying)
  • Award

    Restricted Stock Units

    [F2][F3]
    2026-06-25+2,4172,417 total
    Common Stock (2,417 underlying)
  • Award

    Restricted Stock Units

    [F2][F4]
    2026-06-25+806806 total
    Common Stock (806 underlying)
Footnotes (4)
  • [F1]Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
  • [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
  • [F3]RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
  • [F4]RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Signature
/s/ Scott Sieckert, Attorney-in-Fact|2026-06-29

Documents

1 file
  • 4
    wk-form4_1782765056.xmlPrimary

    FORM 4